Background: Mastalgia, or breast pain, affects 60–70% of women during their lifetime, with 10–20% experiencing severe symptoms. It is categorized as cyclical, non-cyclical, or extramammary. While some cases resolve spontaneously, others persist and may require medical management. Despite the availability of various treatments, a consistently effective and well-tolerated option remains elusive. This study aimed to compare the effectiveness of Ormeloxifene and Evening Primrose Oil (EPO) in the management of mastalgia and fibrocystic breast disease. Methods: A prospective study was conducted among 90 women presenting with mastalgia, divided into two groups of 45 each. Group 1 received Ormeloxifene 30 mg, while Group 2 received Evening Primrose Oil 1000 mg. Participants were followed up at regular intervals, and pain was assessed using the Visual Analogue Scale (VAS) and Cardiff Breast Pain Score. Results: Mastalgia was most common in the 26–35-year age group, with acyclic pain reported more frequently than cyclic. Both groups demonstrated a reduction in pain over time; however, the decline in mean VAS scores was greater in the Ormeloxifene group. Significant differences in pain reduction were observed at the third and fourth visits (p<0.05), indicating a faster and more pronounced response with Ormeloxifene. Conclusions: Ormeloxifene demonstrated a more rapid and sustained reduction in mastalgia symptoms compared to Evening Primrose Oil, suggesting its superiority as a treatment option for benign breast pain.

Mastalgia, fibrocystic breast disease, evening primrose oil